Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Rating of “Moderate Buy” from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $104.71.

LNTH has been the subject of a number of research reports. Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, JMP Securities reissued a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a report on Friday, February 23rd.

Insider Transactions at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold a total of 94,545 shares of company stock valued at $6,169,936 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. Tucker Asset Management LLC boosted its stake in Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 282 shares during the last quarter. Principal Securities Inc. bought a new position in Lantheus during the fourth quarter valued at approximately $28,000. First Horizon Advisors Inc. boosted its stake in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares during the last quarter. West Tower Group LLC boosted its stake in Lantheus by 534.1% during the fourth quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 438 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Lantheus by 60.2% during the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 160 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Up 1.4 %

LNTH stock opened at $62.33 on Friday. The stock has a market capitalization of $4.27 billion, a P/E ratio of 13.43 and a beta of 0.53. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. Lantheus has a 1-year low of $50.20 and a 1-year high of $100.85. The business has a fifty day moving average price of $60.66 and a 200-day moving average price of $62.99.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The company had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. Equities analysts forecast that Lantheus will post 5.72 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.